SCHEMBL29420172

SCHEMBL29420172

O=[N+]([O-])c1ccc(/C(=N\O)c2ccccc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 2/20 0.65
CES2 O00748 1/20 0.65
TDP1 Q9NUW8 1/20 0.55
POLB P06746 2/20 0.54
MAPK1 P28482 1/20 0.54
ALDH1A1 P00352 5/20 0.54
LMNA P02545 2/20 0.54
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
NPC1 O15118 1/20 0.51
MITF O75030 1/20 0.51
RAB9A P51151 1/20 0.51
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
SRD5A2 P31213 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
BCHE P06276 1/20 0.49
MAOB P27338 1/20 0.49
CYP1B1 Q16678 1/20 0.49
CRHBP P24387 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1140280 1.00 CES1 (0.65) CES1CES2TDP1POLBMAPK1
SCHEMBL16690236 0.95 POLB (0.63) CES1CES2TDP1POLBMAPK1
SCHEMBL7353197 0.92 CES1 (0.59) CES1CES2TDP1POLBMAPK1
SCHEMBL12418538 0.84 ACHE (0.64) CES1CES2TDP1POLBMAPK1
SCHEMBL7095150 0.84 CES1 (0.62) CES1CES2TDP1POLBMAPK1
SCHEMBL13029991 0.84 ACHE (0.64) CES1CES2TDP1POLBMAPK1
SCHEMBL27578404 0.81 POLB (0.51) CES1CES2TDP1POLBMAPK1
SCHEMBL9670443 0.80 CES1 (0.74) CES1CES2TDP1POLBMAPK1
SCHEMBL28930611 0.80 CES1 (0.74) CES1CES2TDP1POLBMAPK1
SCHEMBL28949248 0.80 CES1 (0.74) CES1CES2TDP1POLBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250320251-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING NOVEL CYCLIC PEPTIDES LISATA THERAPEUTICS INC (US) 2025-10-16 US claimed
US-20240247032-A1 METHOD OF SYNTHESIZING DENDRIMERIC AMPHIPHILE KAOHSIUNG MEDICAL UNIVERSITY (TW) 2024-07-25 US claimed
EP-4392071-A1 METHOD OF SYNTHESIZING DENDRIMERIC AMPHIPHILE Kaohsiung Medical University (TW) 2024-07-03 EP claimed
CN-117946306-B Diketoxime resin, preparation method thereof and nickel removal method of lithium battery recovery liquid 江苏海普功能材料有限公司 2024-06-07 CN claimed
CN-117946306-A Diketoxime resin, preparation method thereof and nickel removal method of lithium battery recovery liquid 江苏海普功能材料有限公司 2024-04-30 CN claimed
CN-117004836-A Method for extracting scandium element from titanium white waste acid and red mud solution 广西大学 2023-11-07 CN claimed
CN-116497528-A Flexible conductive fiber film based on oxime urethane bond, preparation method and application 陕西科技大学 2023-07-28 CN claimed
WO-2023023889-A1 METHOD OF SYNTHESIZING DENDRIMERIC AMPHIPHILE KAOHSIUNG MEDICAL UNIVERSITY (CN) 2023-03-02 WO claimed
EP-4100007-A1 ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF The Regents of the University of California (US) 2022-12-14 EP claimed
CN-115461054-A Elongation factor 1-alpha inhibitor and application thereof 加利福尼亚大学董事会 2022-12-09 CN claimed
EP-4731637-A1 METHODS OF CHEMICAL SYNTHESIS OF PEPTIDES Imperial College Innovations Limited (GB) 2026-04-29 EP disclosed
EP-4727653-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF Mariana Oncology Inc. (US) 2026-04-22 EP disclosed
EP-4727655-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF Mariana Oncology Inc. (US) 2026-04-22 EP disclosed
EP-4727654-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF Mariana Oncology Inc. (US) 2026-04-22 EP disclosed
EP-4707386-A1 ARTIFICIAL VIRUS CAPSID AGC INC. (JP) 2026-03-11 EP disclosed
US-20220119440-A1 PEPTIDE AND METHOD FOR MANUFACTURING SAME AGC Inc. (JP) 2022-04-21 US disclosed
US-11306074-B2 Chemical and method for analyzing DNA sequence by visualizing single-molecule DNA and use thereof Sogang University Research Foundation (KR) 2022-04-19 US disclosed
US-20220096594-A1 MACROCYCLIC PEPTIDES FOR TARGETED INHIBITION OF AUTOPHAGY BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-03-31 US disclosed
US-11286280-B2 Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy PALATIN TECHNOLOGIES, INC. (US) 2022-03-29 US disclosed
US-20220088146-A1 Melanocortin Receptor-Specific Peptide Formulations and Methods for Gastrointestinal Tract-Specific Delivery PALATIN TECHNOLOGIES INC (US) 2022-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250320251-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING NOVEL CYCLIC PEPTIDES VIP, NGLY1, GRPR CES1 1257/4885CES2 4223/4885TDP1 3912/4885
US-11286280-B2 Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy MC3R, MC1R, MC2R CES1 3705/4885CES2 4725/4885TDP1 3676/4885
US-20220088146-A1 Melanocortin Receptor-Specific Peptide Formulations and Methods for Gastrointestinal Tract-Specific Delivery MC3R, GIPR, MC1R CES1 2485/4885CES2 4292/4885TDP1 4749/4885
US-20240247032-A1 METHOD OF SYNTHESIZING DENDRIMERIC AMPHIPHILE DNM2, ANXA2, ANXA6 CES1 4569/4885CES2 3966/4885TDP1 3109/4885
US-20220119440-A1 PEPTIDE AND METHOD FOR MANUFACTURING SAME VIP, RFC2, QRFPR CES1 1277/4885CES2 2111/4885TDP1 4160/4885
US-11306074-B2 Chemical and method for analyzing DNA sequence by visualizing single-molecule DNA and use thereof FEN1, POLR1A, DCLRE1A CES1 3073/4885CES2 4716/4885TDP1 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.